Fragment 177-191 CAS : 221231-10-3 Peptides Hormone AOD9604 for Weight Loss


AOD9604 is a peptide fragment (hGH Fragment 177-191) of the C-terminus of Human Growth Hormone to which a tyrosine is added at the N-terminal end. Studies have suggested that AOD9604 is more effective than its predecessor AOD9401 in its ability to stimulate lipolytic (fat burning) and anti-lipogenic activity. Like Growth Hormone, AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (prevents the transformation of fatty food materials into body fat) both in laboratory testing and in animals and humans. Recent clinical research studies have shown that AOD9604 did show a reduction of body fat in the mid abdominal area in both obese, over-weight, and average built people.


-------------------------------------------------------------------------------


AOD9604 Peptide Weight loss powder

Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Molecular formula: C78H123N23O23S2
MW : 1815.08152
CAS number: 221231-10-3
PubChem: CID 71300630
Synonyms: Fragment 177-191, AOD-9604
Appearance: White Powder
Purity : 99.3%
Grade : Pharmaceutical Grade
Storage: Closed, below 2 ~ 8oC preservation
Related substance: Total Impurities(%) ≤ 2.0%
Acetate content: ≤ 15.0%
Bacterial Endotoxins: ≤5 IU/mg
Usage : AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.


--------------------------------------------------------------------------------

The Development of AOD9604 from Human Growth Hormone :

Investigators at Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 177-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural Growth Hormone regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified Growth Hormone.


--------------------------------------------------------------------------------

The Fat Loss Properties of AOD 9604 :

In laboratory tests on fat cells from rodents, pigs, dogs, and humans, the HGH fragment released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, enhanced the burning of fat. In rodents (rats and mice), HGH fragment reduced body fat in obese animals but, enhanced fat burning without changing food consumption or inducing growth (as it does not increase IGF levels) or any other unwanted Growth Hormone effect. Recent research has shown AOD9604 to be an extremely potent and effective fat burner. Metabolic is developing AOD-9604 for the potential treatment of obesity. Research studies have shown that AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.

These segments of the synthetic peptide AOD9604 have been researched for their in vivo effects in laboratory mice musculus. Results have shown that AOD9604 have resulted to a short-period increase in blood glucose and a more sustained increase in plasma insulin, together with other fragments such as 172-191, 177-191 and 178-191. In addition, the researchers have suggested that functionality of the peptide depends not only in the informational sequence but should also have the correct physical configuration (Ng and Borstein 1978). Also, AOD9604, being a region of high accessibility to proteases and also rich in proline, have been demonstrated to affect the conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein by serving as the hinge for the pivoting of the two subdomains. This then suggest that such residue is significant in conformational changes be serving as sites for peripheral protein binding in some body cells (Low et al. 1984).


Peptides

HGH 176-191 2mg/vial 10vials/kit 1g/bag
GHRP-2 5mg/vial 10vials/kit 1g/bag
GHRP-2 10mg/vial 10vials/kit 1g/bag
GHRP-6 5mg/vial 10vials/kit 1g/bag
GHRP-6 10mg/vial 10vials/kit 1g/bag
MGF 2mg/vial 10vials/kit 1g/bag
PEG MGF 2mg/vial 10vials/kit 1g/bag
CJC-1295 with DAC 2mg/vial 10vials/kit 1g/bag
CJC-1295 without DAC 2mg/vial 10vials/kit 1g/bag
PT-141 10mg/vial 10vials/kit 1g/bag
Melanotan-1 10mg/vial 10vials/kit 1g/bag
Melanotan-2 10mg/vial 10vials/kit 1g/bag
Ipamorelin 2mg/vial 10vials/kit 1g/bag
Hexarelin 2mg/vial 10vials/kit 1g/bag
Sermorelin 2mg/vial 10vials/kit 1g/bag
Oxytocin 2mg/vial 10vials/kit 1g/bag
TB500 2mg/vial 10vials/kit 1g/bag
Pentadecapeptide BPC 157 2mg/vial 10vials/kit 1g/bag
Triptorelin 2mg/vial 10vials/kit 1g/bag
Gonadorelin 2mg/vial 10vials/kit 1g/bag
Gonadorelin 10mg/vial 10vials/kit 1g/bag
Tesamorelin 2mg/vial 10vials/kit 1g/bag
DSIP 2mg/vial 10vials/kit 1g/bag
Selank 5mg/vial 10vials/kit 1g/bag



Hot selling market :

United State(USA) , United Kingdom(UK) , Australia , Canada , Spain , France , Germany , Russia , Brasil(Brazil) , Ukraine , South Africa , Norway , Poland , Netherlands(Holland) , Slovakia , Georgia , New Zealand , Sweden etc.


North America Market :

United State(USA) , Canada , Mexico , Guatemala , Belize , El Salvador , Honduras , Nicaragua , Costa Rica , Panama , Bahamas , Cuba , Jamaica , Haiti , Dominica , Puerto Rico , Anguilla , Antigua and Barbuda , Montserrat , Guadeloupe , Commonwealth of Dominica , Martinique , Saint Lucia , Barbados , Grenada , Trinidad and Tobago , Aruba etc.


South American markets:

Brasil(Brazil) , Peru , Argentina , Colombia , Venezuela , Guyana , Surinam , Ecuador , Bolivia , Chile , Paraguay , Uruguay etc.


Oceania market :

Australia , New Zealand , Papua New Guinea , Solomon Islands , Northern Mariana Islands , Vanuatu , Palau , Nauru , Tuvalu , Kiribati , Samoa , Niue , Cook Islands , Tonga , Polynesia , Pitcairn , New Caledonia , Fiji , Federated States of Micronesia , Guam , Tokelau , Wallis and Futuna etc.


European market :

Albania , Andorra , Belgium , Germany , Bulgaria , Denmark , Estonia , Finland , France , Greece , United Kingdom (UK) , Ireland , Iceland , Italy , Croatia , Latvia , Liechtenstein , Lithuania , Luxembourg , Macedonia , Malta , Monaco , Netherlands(Holland) , Norway , Austria , Poland , Portugal , Romania , San Marino , Sweden , Switzerland , Slovakia , Slovenia , Spain , Czech , Hungary , Vatican etc.